Roche Maintained at Buy as BofA Notes Bullish View on Giredestrant

08:58 AM EDT, 10/15/2026 (MT Newswires) -- BofA Global Research reiterated its rating on Roche (RO.SW), highlighting its optimistic view on the Swiss pharmaceutical giant's investigational breast cancer drug giredestrant. "Our bullish view on a giredestrant lidERA launch end-26E remains core to our Buy thesis and likely also explains a large part of Roche's share price strength since mid-year (in addition to lack of binary event risk relative to other names in the sector). Cons assumes cCHF6.5bn risk-adjusted 33E sales for giredestrant, with us above at cCHF8bn peak, and buyside expectations similar. Any competitive risk is therefore important, particularly given ROP is currently perceived as a non-binary growth hiding place in the sector by many generalist investors," analysts said Thursday. "Overall, while positive competitor switch data may pose a risk to sentiment, we see limited impact to our gire peak sales, given we think both upfront and switch strategies can co-exist. The research firm also noted the drugmaker's busy pipeline over the next two years, including a potential launch of divarasib in second-line lung cancer and approval of multiple sclerosis treatment fenebrutinib in 2027. The stock's price objective stands at 415 francs.